Validity of prognostic analysis of Adjuvant! Online at Erasto Gaertner Hospital

Authors

  • Sérgio Bruno Bonatto Hatschbach Chefe do Serviço de Ginecologia e Mama do Hospital Erasto Gaertner, Curitiba, PR.
  • Leonardo Dequech Gavarrete Médico-residente de Cancerologia Cirúrgica do Hospital Erasto Gaertner, Curitiba, PR.
  • Thatiana Tiemi Ikeda Acadêmica de Medicina da Pontifícia Universidade Católica do Paraná (PUC-PR).
  • José Clemente Linhares Médicos titulares do Serviço de Ginecologia e Mama do Hospital Erasto Gaertner, Curitiba, PR.
  • João Antônio Guerreiro Médicos titulares do Serviço de Ginecologia e Mama do Hospital Erasto Gaertner, Curitiba, PR.
  • Claudiane Ligia Minari Médicos titulares do Serviço de Ginecologia e Mama do Hospital Erasto Gaertner, Curitiba, PR.

Keywords:

Breast cancer, Adjuvant chemotherapу, Prognosis, Validation, Software, Mortality

Abstract

Adjuvant! is a computer of worldwide computer used by oncologists to decide the adjuvant systemic therapy of
Early Breast Cancer, but has only been tested and validated in thepopulation of U.S. and British, never before tested in populations of least developing countries. Methods: Selected 181 patients with breast cancer stage
Iand IItreated over 10-years ago and implemented the programme variables to forecast the overall mortality,
cancer specific mortality, survival free of disease and likelihood ofrecurrence in 10-years. We compared the
average of all patients with the outcome observed. Results: The biggest difference between the predicted and
observed was 6.4% in the calculation ofthe death by cancer, as the overall mortality difference was 4% and
the difference between the interval free of disease was 3.1%. Conclusion: There was no statistically significant difference between the values, demonstrating the program be a good tool in this institution.

Downloads

Download data is not yet available.

References

1. ParkA. Breast-cancer basics. Diagnosis and treatment keep changing.

Here's what you need to know now. Time. 2007; 170(16):46-7.

2.

3.

Albain K, Green S, Ravdin P, Cobau C, Levine E, Ingle J, et al.

Overall survival after cyclophosphamide, adriamycin, 5FU and

tamoxifen is superior to tamoxifen alone in postmenopausal, rеceptor (+), node (+) breast cancer: new findings from phase III

Southwest Oncology Group Intergroup trial $8814 (INT-0100)

(abstract). Proc Am Soc Clin Oncol. 2001;20:24a.

Goldhirsch A, Gelber RD, Castiglione M. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group.

Ann Oncol. 1990;1:183-88.

4. Colleoni M, Gelber S, Goldhirsch A, et al. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph nodepositive breast cancer: International Breast Cancer Study Group

Trial 13-93. J Clin Oncol. 2006;24:1332-41.

5. Goldhirsch A, Coates AS, Colleoni M, Castiglione-Gertsch M,

Gelber RD. Adjuvant chemoendocrine therapy in postmenopausal breast cancer: cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. International Breast

Cancer Study Group.J Clin Oncol. 1998;16:1358-62.

6. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and

adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353:1784-92.

7. Luke C, Gill G, Birrell S, Humeniuk V, Borg M, Karapetis C, et

al. Treatment and survival from breast cancer: the experience of

patients at South Australian teaching hospitals between 1977 and

2003. J Eval Clin Pract. 2006;13(2):212-20.

8. Kenemans P. Quality of life in breast cancer patients. Gynecological Endocrinology: The Official Journal of the International

Society of Gynecological Endocrinology. Gynecol Endocrinol.

2007;23(7):366-7.

9. Habel LA, Shak S, Jacobs MK, et al. A population-based study of

tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res. 2006;8:R25.

10. Masood S. The knowledge about risk for breast cancer: the patients

right to know. Breast J. 2008;14(3):219-20.

11. Richards MA, O'Reilly SM, Howell A, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with axillary

node-positive breast cancer: an update of the Guy's/Manchester

trial. J Clin Oncol. 1990;8:2032-39.

12. Fisher B, Dignam J, BryantJ, Wolmark N. Five versus more than five

years of tamoxifen for lymph node-negative breast cancer: updated

findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst. 2001;93:684-90.

13. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24:3726-34.

14. Ravdin P, Simonoff LA, Davis GJ, et al. Computer program to

assist in making decisions about adjuvant therapy for women with

early breast cancer. J Clin Oncol. 2001;19(4):980-91.

15. Olivotto IA, Bajdik CD, Ravdin PM, et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol. 2005;23:2716-25.

Downloads

Published

2026-07-26

How to Cite

Hatschbach, S. B. B., Gavarrete, L. D., Ikeda, T. T., Linhares, J. C., Guerreiro, J. A., & Minari, C. L. (2026). Validity of prognostic analysis of Adjuvant! Online at Erasto Gaertner Hospital. Mastology, 18(4). Retrieved from https://mastology.org/journal/article/view/2030

Issue

Vol. 18 No. 4 (2008)

Section

Original Articles

License

Copyright (c) 2026 Sérgio Bruno Bonatto Hatschbach, Leonardo Dequech Gavarrete, Thatiana Tiemi Ikeda, José Clemente Linhares, João Antônio Guerreiro, Claudiane Ligia Minari

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.